Ingredients For WHO Roadmap On Access To Medicines At Civil Society Side Event 25/05/2018 by Catherine Saez, Intellectual Property Watch 2 Comments On the side of this week’s World Health Assembly and hours before the Assembly agreed on preparing a roadmap on access to medicines, two civil society groups held an event on the same subject. The Brazilian ambassador, a senior official from the Netherlands, and a WHO assistant director general among others delivered their thoughts on the issue and the way forward. Key words were high prices, transparency, and trade flexibilities.
50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 by William New, Intellectual Property Watch Leave a Comment Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as “do-ers” and partners in global health progress. Cueni also talks about pricing and cost of R&D.
Five Years After The Indian Supreme Court’s Novartis Verdict 20/05/2018 by Patralekha Chatterjee for Intellectual Property Watch 13 Comments On 1 April 2013, in a packed room inside India’s Supreme Court, a magnificent building in Indo-British architectural style, two judges delivered a verdict that impacted the national and global conversation about patents and patients. India’s apex court delivered a 112-page landmark judgement which dismissed Swiss pharma giant Novartis AG’s appeal for a patent for its life-saving cancer drug marketed under brand name Glivec in most parts of the world. The Novartis case triggered a hugely polarising discourse around the world about a key feature of India’s patent regime.
Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say 18/05/2018 by Dugie Standeford for Intellectual Property Watch 17 Comments For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say.
Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents 10/05/2018 by Catherine Saez, Intellectual Property Watch 14 Comments Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries, civil society organised itself to increase access to sofosbuvir for millions in need.
Truvada Case Shows Civil Society’s Success With Pre-Grant Opposition 08/05/2018 by Catherine Saez, Intellectual Property Watch 15 Comments The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to patents it felt were unjustified were rewarded by patent withdrawal and rejection, even if the situation in Brazil might not be entirely settled.
Evergreened Patents Cause Unwarranted High Drug Prices, Hinder Growth Of Local Producers – NGOs, Thai Producers Claim 07/05/2018 by Sinfah Tunsarawuth for Intellectual Property Watch 17 Comments BANGKOK – Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic generic drug industry, costing the Thai government hundreds of millions of dollars, drug access campaigners and local producers have said.
New Guidelines For Tech Companies To Be Transparent, Accountable On Censoring User Content 07/05/2018 by Intellectual Property Watch 2 Comments Facebook, Google and other social media companies today were urged by groups such as the Electronic Frontier Foundation to “publicly report how many user posts they take down, provide users with detailed explanations about takedowns, and implement appeals policies to boost accountability.” The groups released a set of guidelines to address censorship.
Civil Society Key In TRIPS Flexibility Implementation 04/05/2018 by Catherine Saez, Intellectual Property Watch 22 Comments When the agreement on intellectual property was adopted by the World Trade Organization, a number of flexibilities were included in the text, mainly to give developing countries policy space to implement the agreement with development considerations. However, some countries through lack of awareness or economic pressure have not used those flexibilities fully, and found themselves facing difficulties addressing their public health needs, which some associate with this failure to use the flexibilities. Civil society has engaged in notable efforts to counter pressure and raise policymakers’ awareness for a wider access to medicines.
Ukraine Eyes Patent Law Reform After Civil Society Push On Medicines Access 30/04/2018 by Dugie Standeford for Intellectual Property Watch 14 Comments Ukrainian lawmakers are poised to approve sweeping patent reform legislation, driven in large part by a push by patients’ groups for better access to affordable medicines and healthcare.